In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 531 other companies have achieved higher Quick Ratio than Cell Source Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 4706 to 5141.

Explain Quick Ratio?
How much Cash & cash equivalents CLCS�s has?
What are CLCS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLCS Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	26.17 %	6.24 %	61.83 %	33.68 %	67.04 %
Y / Y Cash & cash equivalent Change	5291.3 %	236.13 %	4.54 %	-31.92 %	-99.99 %
Quick Ratio MRQ	0	0.02	0	0.02	0
CLCS's Total Ranking	# 5141	# 4706	# 4618	# 3970	# 4756
Seq. Current Liabilities Change	32.52 %	-19.42 %	10.27 %	7.16 %	11.58 %
Seq. Cash & cash equivalent Change	-98.34 %	224.6 %	-74.61 %	393591.3 %	-99.9 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 532
Healthcare Sector	# 1056
Overall Market	# 5141

Quick Ratio Statistics
High	Average	Low
0.32	0.02	0
(Jun 30 2014)		(Mar 31 2024)

Financial Statements
Cell Source Inc 's Current Liabilities	$ 6 Millions	Visit CLCS's Balance sheet
Cell Source Inc 's Cash & cash equivalent	$ 0 Millions	Visit CLCS's Balance sheet
Source of CLCS's Sales		Visit CLCS's Sales by Geography

Cumulative Cell Source Inc 's Quick Ratio

CLCS's Quick Ratio for the trailling 12 Months

CLCS Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	30.31 %	38.94 %	46.5 %	32.98 %	35.44 %
Y / Y Cash & cash equivalent TTM Growth	6.87 %	-52.94 %	-69.39 %	-68.23 %	-58.12 %
Quick Ratio TTM	0.01	0.01	0.01	0.01	0.01
Total Ranking TTM	#	#	#	#	#
Seq. Current Liabilities TTM Growth	6.22 %	1.35 %	12.21 %	7.88 %	13.26 %
Seq. Cash & cash equivalent TTM Growth	0.65 %	38.62 %	0.74 %	-23.96 %	-55.68 %

Quick ratio ranking by company, industry and sector >> Back to CLCS Financial Strength Comparisons >> Go to Compare CLCS Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the growth in Current Liabilities in the Q1 2025 to $6.38 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Cell Source Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 531 other companies have achieved higher Quick Ratio than Cell Source Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents CLCS�s has?
What are CLCS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 532
Healthcare Sector	# 1056
Within the Market	# 5141

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.32	0.02	0
(Jun 30 2014)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Semnur Pharmaceuticals Inc	0.00	$ 0.003 Millions	$ 7.852 Millions
Cell Source Inc	0.00	$ 0.001 Millions	$ 6.379 Millions
One World Products Inc	0.00	$ 0.000 Millions	$ 3.376 Millions

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.